|
1
|
Hosomi Y, Morita S, Sugawara S, Kato T,
Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, et
al: Gefitinib alone versus gefitinib plus chemotherapy for
non-small-cell lung cancer with mutated epidermal growth factor
receptor: NEJ009 study. J Clin Oncol. 38:115–123. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xu CW, Wang G, Wang WL, Gao WB, Han CJ,
Gao JS, Li Y, Wang L, Zhang LY, Zhang YP, et al: Association
between epidermal growth factor receptor mutations and the
expression of excision repair cross-complementing protein 1 and
ribonucleotide reductase subunit M1 mRNA in patients with non-small
cell lung cancer. Exp Ther Med. 9:880–884. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xie Y, Liang J and Su N: Gefitinib versus
Erlotinib as first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Nan Fang Yi Ke Da Xue
Xue Bao. 35:446–449. 2015.PubMed/NCBI(In Chinese).
|
|
5
|
Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM,
Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, et al: Afatinib for
patients with lung adenocarcinoma and epidermal growth factor
receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol.
13:539–548. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fiala O, Pesek M, Finek J, Svaton M,
Minarik M, Benesova L, Bortlicek Z, Kucera R and Topolcan O:
Pemetrexed versus erlotinib in the second-line treatment of
patients with advanced-stage non-squamous NSCLC harboring wild-type
EGFR gene. Anticancer Res. 36:447–453. 2016.PubMed/NCBI
|
|
8
|
Lopes GL, Vattimo EF and Castro Junior Gd:
Identifying activating mutations in the EGFR gene: Prognostic and
therapeutic implications in non-small cell lung cancer. J Bras
Pneumol. 41:365–375. 2015.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
9
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Final overall
survival results from a randomised, phase III study of erlotinib
versus chemotherapy as first-line treatment of EGFR
mutation-positive advanced non-small-cell lung cancer (OPTIMAL,
CTONG-0802). Ann Oncol. 26:1877–1883. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang JC, Srimuninnimit V, Ahn MJ, Lin CC,
Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X and Park K:
First-line pemetrexed plus cisplatin followed by gefitinib
maintenance therapy versus gefitinib monotherapy in East Asian
never-smoker patients with locally advanced or metastatic
nonsquamous non-small cell lung cancer: Final overall survival
results from a randomized phase 3 study. J Thorac Oncol.
11:370–379. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hotta K, Kiura K, Toyooka S, Takigawa N,
Soh J, Fujiwara Y, Tabata M, Date H and Tanimoto M: Clinical
significance of epidermal growth factor receptor gene mutations on
treatment outcome after first-line cytotoxic chemotherapy in
Japanese patients with non-small cell lung cancer. J Thorac Oncol.
2:632–637. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Okamoto I, Aoe K, Kato T, Hosomi Y,
Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, et
al: Pemetrexed and carboplatin followed by pemetrexed maintenance
therapy in chemo-naïve patients with advanced nonsquamous
non-small-cell lung cancer. Invest New Drugs. 31:1275–1282.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Qin N, Zhang Q, Wang J, Zhang H, Gu Y,
Yang X, Li X, Lv J, Wu Y, Nong J, et al: Association between the
epidermal growth receptor status and the efficacy of
first-line
chemotherapy in patients with advanced non-small cell lung cancer.
Zhongguo Fei Ai Za Zhi. 18:131–137. 2015.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
15
|
Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z
and Han JQ: EGFR mutations and clinical outcomes of chemotherapy
for advanced non-small cell lung cancer: A meta-analysis. Lung
Cancer. 85:339–345. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu J, Zhang J, Chen M and Zhou CC:
Outcomes of chemotherapy in patients with EGFR mutation-negative
non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:386–388.
2013.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
17
|
Lou N, Yang J, Yan H, Zhou Q, Liao R, Xu
C, Huang Y, Yang X, Yang Y, Gan B and Wu Y: Efficacies of gefitinib
versus paclitaxel/carboplatin for patients with advanced pulmonary
adenocarcinoma. Zhonghua Yi Xue Za Zhi. 94:2337–2341.
2014.PubMed/NCBI(In Chinese).
|
|
18
|
Park JH, Lee SH, Keam B, Kim TM, Kim DW,
Yang SC, Kim YW and Heo DS: EGFR mutations as a predictive marker
of cytotoxic chemotherapy. Lung Cancer. 77:433–437. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
21
|
Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu
X, Tong X and Yu X: Mutational profiling of non-small-cell lung
cancer patients resistant to first-generation EGFR tyrosine kinase
inhibitors using next generation sequencing. Oncotarget.
7:61755–61763. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee. The IASLC lung cancer staging
project: Proposals for the revision of the TNM stage groupings in
the forthcoming (seventh) edition of the TNM classification of
malignant tumours. J Thorac Oncol. 2:706–714. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nishino M, Jackman DM, Hatabu H, Yeap BY,
Cioffredi LA, Yap JT, Jänne PA, Johnson BE and Van den Abbeele AD:
New response evaluation criteria in solid tumors (RECIST)
guidelines for advanced non-small cell lung cancer: Comparison with
original RECIST and impact on assessment of tumor response to
targeted therapy. AJR Am J Roentgenol. 195:W221–W228.
2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang W, Mao Y, Zhan Y, Huang J, Wang X,
Luo P, Li LI, Mo D, Liu Q, Xu H and Huang C: Prognostic
implications of survivin and lung resistance protein in advanced
non-small cell lung cancer treated with platinum-based
chemotherapy. Oncol Lett. 11:723–730. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kang X, Xiao HH, Song HQ, Jing XB, Yan LS
and Qi RG: Advances in drug delivery system for platinum agents
based combination therapy. Cancer Biol Med. 12:362–374.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tamura T, Kurishima K, Nakazawa K,
Ishikawa H, Satoh H and Hizawa N: Similar survival benefits of a
good response and sTable disease to platinum-based chemotherapy in
non-small cell lung cancer. Oncol Lett. 10:1135–1140.
2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schuette W, Schirmacher P, Eberhardt WE,
Fischer JR, von der Schulenburg JM, Mezger J, Schumann C, Serke M,
Zaun S, Dietel M and Thomas M: EGFR mutation status and first-line
treatment in patients with stage III/IV non-small cell lung cancer
in Germany: An observational study. Cancer Epidemiol Biomarkers
Prev. 24:1254–1261. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fang S, Wang Z, Guo J, Liu J, Li C, Liu L,
Shi H, Liu L, Li H, Xie C, et al: Correlation between EGFR mutation
status and response to first-line platinum-based chemotherapy in
patients with advanced non-small cell lung cancer. Onco Targets
Ther. 7:1185–1193. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kalikaki A, Koutsopoulos A, Hatzidaki D,
Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V
and Voutsina A: Clinical outcome of patients with non-small cell
lung cancer receiving front-line chemotherapy according to EGFR and
K-RAS mutation status. Lung Cancer. 69:110–115. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lee KH, Han SW, Hwang PG, Oh DY, Kim DW,
Chung DH, Im SA, Kim TY, Heo DS and Bang YJ: Epidermal growth
factor receptor mutations and response to chemotherapy in patients
with non-small-cell lung cancer. Jpn J Clin Oncol. 36:344–350.
2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yoshimasu T, Oura S, Ohta F, Hirai Y,
Naito K, Nakamura R, Nishiguchi H, Hashimoto S, Kawago M and
Okamura Y: Epidermal growth factor receptor mutations are
associated with docetaxel sensitivity in lung cancer. J Thorac
Oncol. 6:1658–1662. 2011.PubMed/NCBI View Article : Google Scholar
|
